Parental exposure to antidepressants has lasting effects on offspring? A case study with zebrafish

Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved..

Fish have common neurotransmitter pathways with humans, exhibiting a significant degree of conservation and homology. Thus, exposure to fluoxetine makes fish potentially susceptible to biochemical and physiological changes, similarly to what is observed in humans. Over the years, several studies demonstrated the potential effects of fluoxetine on different fish species and at different levels of biological organization. However, the effects of parental exposure to unexposed offspring remain largely unknown. The consequences of 15-day parental exposure to relevant concentrations of fluoxetine (100 and 1000 ng/L) were assessed on offspring using zebrafish as a model organism. Parental exposure resulted in offspring early hatching, non-inflation of the swimming bladder, increased malformation frequency, decreased heart rate and blood flow, and reduced growth. Additionally, a significant behavioral impairment was also found (reduced startle response, basal locomotor activity, and altered non-associative learning during early stages and a negative geotaxis and scototaxis, reduced thigmotaxis, and anti-social behavior at later life stages). These behavior alterations are consistent with decreased anxiety, a significant increase in the expression of the monoaminergic genes slc6a4a (sert), slc6a3 (dat), slc18a2 (vmat2), mao, tph1a, and th2, and altered levels of monoaminergic neurotransmitters. Alterations in behavior, expression of monoaminergic genes, and neurotransmitter levels persisted until offspring adulthood. Given the high conservation of neuronal pathways between fish and humans, data show the possibility of potential transgenerational and multigenerational effects of pharmaceuticals' exposure. These results reinforce the need for transgenerational and multigenerational studies in fish, under realistic scenarios, to provide realistic insights into the impact of these pharmaceuticals.

Medienart:

E-Artikel

Erscheinungsjahr:

2024

Erschienen:

2024

Enthalten in:

Zur Gesamtaufnahme - volume:355

Enthalten in:

Chemosphere - 355(2024) vom: 18. Apr., Seite 141851

Sprache:

Englisch

Beteiligte Personen:

Correia, Daniela [VerfasserIn]
Bellot, Marina [VerfasserIn]
Goyenechea, Júlia [VerfasserIn]
Prats, Eva [VerfasserIn]
Moro, Hugo [VerfasserIn]
Gómez-Canela, Cristian [VerfasserIn]
Bedrossiantz, Juliette [VerfasserIn]
Tagkalidou, Niki [VerfasserIn]
Ferreira, Carla S S [VerfasserIn]
Raldúa, Demetrio [VerfasserIn]
Domingues, Inês [VerfasserIn]
Faria, Melissa [VerfasserIn]
Oliveira, Miguel [VerfasserIn]

Links:

Volltext

Themen:

01K63SUP8D
Antidepressive Agents
Behavior alterations
Embryonic development
Fluoxetine
Journal Article
Monoaminergic system
Neurotransmitter Agents
Parental effects
Persistent effects
Pharmaceutical Preparations
Water Pollutants, Chemical

Anmerkungen:

Date Completed 18.04.2024

Date Revised 18.04.2024

published: Print-Electronic

Citation Status MEDLINE

doi:

10.1016/j.chemosphere.2024.141851

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM370693590